Consumer Driven Health Care

Drug negotiation with manufacturers is government price fixing and is unconstitutional, says the Pharmaceutical Research and Manufacturers of America.

Higher general inflation in medical supplies and pharmaceuticals, combined with staffing issues, have increased costs for providers.

Drugmakers have been rushing to develop obesity pills (to rival obesity shots like Wegovy), angling for a piece of a market that some estimate will one day be worth as much as $100 billion.

Shining a light on one of the biggest mysteries in health care is a noble goal. Here's how employers and benefits advisors can build on the transparency momentum to transform the system.

The main cause, experts agree, is the underlying weakness of the generic drug industry, which are made mostly overseas because U.S. manufacturers are setting their sights instead on high-priced drugs with plump profit margins.

More than 70,000 Zantac lawsuits have been filed against the drugmaker and the other pharmaceutical companies, including Pfizer and Sanofi, that sold the heartburn drug.